New Horizons in Antifungal Therapy
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Recent investigations have yielded both profound insights into the mechanisms required by pathogenic fungi for virulence within the human host, as well as novel potential targets for antifungal therapeutics. Some of these studies have resulted in the identification of novel compounds that act against these pathways and also demonstrate potent antifungal activity. However, considerable effort is required to move from pre-clinical compound testing to true clinical trials, a necessary step toward ultimately bringing new drugs to market. The rising incidence of invasive fungal infections mandates continued efforts to identify new strategies for antifungal therapy. Moreover, these life-threatening infections often occur in our most vulnerable patient populations. In addition to finding completely novel antifungal compounds, there is also a renewed effort to redirect existing drugs for use as antifungal agents. Several recent screens have identified potent antifungal activity in compounds previously indicated for other uses in humans. Together, the combined efforts of academic investigators and the pharmaceutical industry is resulting in exciting new possibilities for the treatment of invasive fungal infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 1×
“Cryptococcosis >1,000,000 [6] 20%–70% [6] Candidiasis >400,000 [7] 10%–75% [8] Aspergillosis >200,000 [9,10] 30%–95% [1,10–12]”
Perfect, J. R., Dismukes, W. E., Dromer, F., Goldman, D. L., Graybill, J. R., Hamill, R. J., Harrison, T. S., Larsen, R. A., Lortholary, O., Nguyen, M.-H., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649858 · Cited by 2,660
Novel perspectives on mucormycosis: pathophysiology, presentation, and management
Spellberg, B., Edwards, J., & Ibrahim, A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.3.556-569.2005 · Cited by 1,537 · cited 1×
“Pneumocystis Pneumonia >400,000 [1,13] 20%–80% [13–15] Mucormycosis (zygomycosis) >11,000 [16] 30%–90% [16,17]”
Histoplasmosis: a Clinical and Laboratory Update
Kauffman, C. A. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00027-06 · Cited by 1,200 · cited 2×
“Blastomycosis ~3000 [4] <2%–68% [1,18,19] Coccidioidomycosis ~20,000 [20] <1%–70% [21] Histoplasmosis ~25,000 [22] 28%–50% [5] Paracoccidioidomycosis ~4000 [23] 5%–27% [23] Penicilliosis >8000 [1] 2%–75% [24,25]”
BackgroundDenning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131 · cited 1×
“These drugs are primarily used for the treatment of invasive candidiasis and as an alternative therapy for treatment of aspergillosis [53].”
BackgroundAntifungal drug resistance: mechanisms, epidemiology, and consequences for treatment
Pfaller, M. A. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.11.001 · Cited by 903
Amphotericin primarily kills yeast by simply binding ergosterol
Gray, K. C., Palacios, D. S., Dailey, I., Endo, M. M., Uno, B. E., Wilcock, B. C., & Burke, M. D. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117280109 · Cited by 608 · cited 5×
“ergosterol binding, but not pore formation, is the key fungicidal feature of amphotericin B [30,119,120].”
BackgroundInfluentialAmphotericin forms an extramembranous and fungicidal sterol sponge
Anderson, T. M., Clay, M. C., Cioffi, A. G., Diaz, K. A., Hisao, G. S., Tuttle, M. D., Nieuwkoop, A. J., Comellas, G., Maryum, N., Wang, S., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1496 · Cited by 528 · cited 2×
“Recent models posit that these drugs act as “sponges” that bind to and remove ergosterol from the plasma membrane, reducing membrane integrity [30,44].”
BackgroundCalcineurin is required for virulence of Cryptococcus neoformans
Odom, A., Muir, S., Lim, E., Toffaletti, D. L., Perfect, J., & Heitman, J. (1997) · The EMBO Journal · doi:10.1093/emboj/16.10.2576 · Cited by 516
Cited by
Campoy, S., & Adrio, J. L. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.11.019 · Cited by 511
The Still Underestimated Problem of Fungal Diseases Worldwide
Almeida, F., Rodrigues, M. L., & Coelho, C. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00214 · Cited by 445
Houšť, J., Spížek, J., & Havlíček, V. (2020) · Metabolites · doi:10.3390/metabo10030106 · Cited by 254
Antifungals discovery: an insight into new strategies to combat antifungal resistance
Fuentefria, A. M., Pippi, B., Dalla Lana, D. F., Donato, K. K., & de Andrade, S. F. (2018) · Letters in Applied Microbiology · doi:10.1111/lam.12820 · Cited by 206
“However, besides problems that are related to resistance, the antifungal drugs have several limitations due to issues with drug safety profiles, pharmacokinetic properties, undesirable side effects, activity spectrum and a small number of targets (Pfaller 2012; Pianalto and Alspaugh 2016).”
BackgroundHasim, S., & Coleman, J. J. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0465 · Cited by 144
The Future of Antifungal Drug Therapy: Novel Compounds and Targets
Mota Fernandes, C., Dasilva, D., Haranahalli, K., McCarthy, J. B., Mallamo, J., Ojima, I., & Del Poeta, M. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01719-20 · Cited by 124
“used in conjunction with polyenes and with azoles, respectively (6, 7, 15, 16).”
BackgroundMethodNovel 1, 2, 4‐Triazoles as Antifungal Agents
Kazeminejad, Z., Marzi, M., Shiroudi, A., Kouhpayeh, S. A., Farjam, M., & Zarenezhad, E. (2022) · BioMed Research International · doi:10.1155/2022/4584846 · Cited by 102
“Annually, invasive fungal infections cause 1.7 million deaths in the world, which is a major public health issue [16].”
InfluentialDevelopment and research progress of anti-drug resistant fungal drugs
Cui, X., Wang, L., Lü, Y., & Yue, C. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.08.004 · Cited by 85
Pfaller, M. A., Huband, M. D., Flamm, R. K., Bien, P. A., & Castanheira, M. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00840-19 · Cited by 80
Synergistic and antagonistic drug interactions in the treatment of systemic fungal infections
Wambaugh, M. A., Denham, S. T., Ayala, M., Brammer, B., Stonhill, M. A., & Brown, J. C. (2020) · eLife · doi:10.7554/elife.54160 · Cited by 65
Multiresistant Fusarium Pathogens on Plants and Humans: Solutions in (from) the Antifungal Pipeline?
Al-Hatmi, A., de Hoog, G. S., & Meis, J. F. (2019) · Infection and Drug Resistance · doi:10.2147/idr.s180912 · Cited by 47
“125 μg/mL) against Fusarium solani.(100) The histone deacetylase 2”
BackgroundPianalto, K. M., Billmyre, R. B., Telzrow, C. L., & Alspaugh, J. A. (2019) · Genetics · doi:10.1534/genetics.119.302290 · Cited by 41
Self-citationZinc and Iron Homeostasis: Target-Based Drug Screening as New Route for Antifungal Drug Development
Simm, C., & May, R. C. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00181 · Cited by 26
Metadata
- Authors
- Pianalto, K., & Alspaugh, J.
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2016-10-02
- Volume
- 2
- Issue
- 4
- Pages
- 26
- ISSN
- 2309-608X (ISSN-L)
- OpenAlex
- W2529676164
- Cited by
- 190
- References
- 61
- FWCI
- 16.52
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.